Anna-Lena Meinhardt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna-Lena Meinhardt has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ajit Kumar Sharma
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
5 shared publications - Amira Kazi
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research , Bethesda, Maryland
5 shared publications - Anish Thomas
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
5 shared publications - Brett Schroeder
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
5 shared publications - Chirayu Mohindroo
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD
5 shared publications - Christopher W. Schultz
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
5 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.